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Summary
Background.— Flow cytometry has shown levels of platelet-derived microparticles (PMPs) and
endothelial-derived microparticles (EMPs) to be elevated in deep-vein thrombosis. Cardiovas-
cular risk factors can also contribute to hypercoagulability due to circulating procoagulantfactors microparticles (CPMPs).
Aims.— To investigate in a case-control study the respective contribution of pulmonary
embolism and cardiovascular risk factors to the level of hypercoagulability due to CPMPs.
Methods.— CPMP, PMP and EMP levels were measured in 45 consecutive patients (age
67.9± 11.6 years; 66.7% men) admitted to an intensive care unit for acute pulmonary embolism
(APE), 45 healthy control subjects with no history of venous thromboembolism or vascular risk
Abbreviations: APE, acute pulmonary embolism; ControlsCVRFs, controls with cardiovascular risk factors; ControlsnoCVRFs, controls without
ardiovascular risk factors; CPMP, circulating procoagulant microparticle; EMP, endothelial-derived microparticle; IQR, interquartile range;
MP, platelet-derived microparticle; VTE, venous thromboembolism.
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factors (ControlsnoCVRFs), and 45 patients with cardiovascular risk factors (ControlsCVRFs). APE
was diagnosed by spiral computed tomography or scintigraphy. CPMP levels were assessed
using a prothrombinase assay on platelet-depleted plasma (results expressed as nmol/L
equivalent).
Results.— CPMP levels were higher in APE patients than in ControlsnoCVRFs (medians 4.7 vs
3.2 nmol/L, interquartile ranges [IQRs] 2.9—11.1 vs 2.3—4.6 nmol/L; p = 0.02). Similar results
were reported for PMPs (medians 2.2 vs 1.9 nmol/L, IQRs 1.7—5.8 vs 1.4—2.4 nmol/L; p = 0.02),
whereas EMP levels were not signiﬁcantly different. However, CPMP procoagulant activity was
not signiﬁcantly different in APE patients and ControlsCVRFs.
Conclusions.— CPMPs and PMPs were signiﬁcantly elevated in APE patients vs ControlsnoCVRFs,
but this correlation was not signiﬁcant when APE patients were compared with ControlsCVRFs.
Our observations highlight the importance of adjusting for the presence of cardiovascular risk
factors in conditions in which microparticle levels are raised.
© 2010 Published by Elsevier Masson SAS.
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Résumé
Contexte.— La thrombose veineuse profonde est associée à une augmentation du niveau de
microparticules (MP) d’origine endothéliale et plaquettaire mesurée en cytométrie de ﬂux. Les
facteurs de risque cardiovasculaires (FRCV) ont aussi une inﬂuence importante sur le niveau
des microparticules.
Objectifs.— Nous avons évalué le niveau des microparticles procoagulantes circulantes chez
des patients admis pour embolie pulmonaire (EP) aiguë et étudié le rôle respectif de la mal-
adie veineuse thrombo-embolique et des facteurs de risque cardiovasculaire sur le niveau
d’hypercoagulabilité lié aux microparticules.
Méthodes.— Les microparticules procoagulantes circulantes, les microparticules plaquettaires
et d’origine endothéliale ont été mesurées chez 45 patients consécutifs (âge 67,9± 11,6,
66,7 % d’homme) admis en unité de soins intensifs pour une embolie pulmonaire aiguë, chez
45 patients sans facteur de risque cardiovasculaire et chez 45 patients avec des facteurs de
risque cardiovasculaire. L’embolie pulmonaire était documentée soit par angioscanner soit par
scintigraphie pulmonaire de ventilation et perfusion. L’activité procoagulante des MP circu-
lantes a été mesurée en utilisant un plasma pauvre en plaquettes et un test fonctionnel à la
prothrombinase.
Résultats.— Les microparticules procoagulantes circulantes étaient plus élevées chez les
patients admis pour une EP (médiane 4,7 nmol/L, interquartile range [IQR] 2,9—11,1) que chez
les patients sans FRCV (médiane 3,2 nmol/L, IQR 2.3—4.6 ; p = 0,01). Le niveau des MP d’origine
plaquettaire était plus élevé chez les patients présentant une EP comparativement aux patients
sans FRCV (médiane 2,2 nmol/L, IQR 1,7—5,8 versus 1,9, 1,4—2,4 ; p = 0,02). Le niveau des MP
d’origine endothéliale était, en revanche, comparable dans les deux populations. Cependant,
le niveau des MP procoagulantes n’était pas signiﬁcativement différent des patients avec FRCV,
et ce, quel que soit le phénotype considéré.
Conclusion.— Les MP procoagulantes totales et plaquettaires sont signiﬁcativement plus
élevées chez les patients admis pour embolie pulmonaire aiguë comparativement à des patients
sans facteur de risque cardiovasculaire. Cette relation n’est plus retrouvée lorsque ces patients
sont comparés à des sujets témoins avec facteurs de risque cardiovasculaire. Ces données
démontrent l’importance de prendre en compte les facteurs de risque cardiovasculaire dans
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Introduction
According to Virchow’s triad, the pathophysiology of
VTE relies on the presence of blood hypercoagula-
bility, stasis of blood ﬂow and vessel-wall damage
[1]. The factors involved in venous thrombogenesis
could be deﬁned as soluble coagulant factors, dys-
functional endothelium and circulating cells, especially
platelets, lymphomonocytes and, potentially, CPMPs
[2,3].
n
c
d
[P.
n SAS.
CPMPs are plasma membrane fragments that are released
nto the blood by stimulated cells during activation or apop-
osis, and carry procoagulant phosphatidylserine and tissue
actor on their surface [4—7]. CPMPs circulate in healthy
umans and support low-grade generation of thrombin [8].
igh levels of CPMPs have been reported in several sce-
arios, including, for example, in patients with an acute
oronary syndrome [9—11] or atrial ﬁbrillation [12]. Car-
iovascular risk factors such as hypertension and diabetes
13—15] have been associated with elevated CPMPs and their
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henotypes. In interpreting the role of CPMPs in thrombo-
enesis, we need to take into account potential cofounders,
he most prevalent of which appear to be cardiovascular risk
actors.
Two previous clinical studies have reported elevated lev-
ls of CPMPs — mainly PMPs and EMPs — by ﬂow cytometry,
n patients hospitalized for deep-vein thrombosis. How-
ver, they had different phenotypic representations, and the
uthors did not take into account potential confounders,
uch as cardiovascular risk factors [16,17]. Experimental
tudies in vivo are supportive of the involvement of human
ell-derived microparticles in venous thrombogenesis in a
issue factor-dependent manner, and have described a cor-
elation of leukocyte- and PMPs with thrombus weight and
issue factor activity [18,19]. Recently, the crucial partic-
pation of circulating tissue factor-bearing microparticles
eleased by tumour cells in cancer-associated hypercoagula-
ility has been emphasized, depending on both the tumour
ell origin and a critical threshold of microparticles [20—24].
n addition, we have shown in a case-control study that CPMP
evels, deﬁned by their procoagulant activity, were elevated
n patients without cancer hospitalized with APE, and we
nalysed the inﬂuence of cardiovascular risk factors on this
orrelation [25].
ethods
tudy subjects
etween November 2004 and December 2005, we included
5 consecutive patients admitted to our intensive care unit
or APE associated with or without deep-vein thrombo-
is, and compared them with 45 healthy controls without
ControlsnoCVRFs) and 45 patients with (ControlsCVRFs) cardio-
ascular risk factors, matched for age and sex. ControlsCVRFs
nd patients with APE were also matched for the presence
f hypertension. Demographic and clinical characteristics
ere recorded prospectively upon enrolment. The study
as approved by the institutional review board and was
erformed in accordance with institutional guidelines. All
atients gave written informed consent before participating
n the study.
cute pulmonary embolism cases
PE was conﬁrmed by spiral computed tomography (n = 25),
entilation-perfusion scintigraphy (n = 20) or both (n = 12).
reatment on admission consisted of standard antithrom-
otic therapy with low-molecular-weight or unfractionated
eparin. Exclusion criteria were conditions known or sus-
ected to increase levels of CPMPs independently, such
s acute coronary syndromes, acute heart failure, stroke,
epsis, chronic inﬂammatory disease, antiphospholipid
yndrome, heparin-induced thrombocytopenia, thrombotic
hrombocytopenic purpura and atrial ﬁbrillation.
Transient VTE risk factors were deﬁned as pregnancy,
estrogen therapy, surgery (< 60 days), trauma, conﬁned
o bed (> 5 days) and recent journey (> 10 hours). Cancer
nd thrombophilia were deﬁned as chronic VTE risk factors.
aemodynamic status was considered over three levels:
ubmassive APE (stable haemodynamics with signs of right
t
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eart failure on transthoracic echocardiography), massive
PE (unstable haemodynamics with right heart failure on
ransthoracic echocardiography) and shock.
ontrols with cardiovascular risk factors
ontrolsCVRFs comprised patients with no history of VTE
r atrial ﬁbrillation who were undergoing routine screen-
ng physical examinations for cardiac symptoms at our
utpatient cardiology clinic, with an electrocardiogram doc-
menting sinus rhythm.
ontrols without cardiovascular risk factors
ontrolsnoCVRF included patients undergoing screening exam-
nation before orthopaedic surgery, with no known cardio-
ascular risk factors, history of atrial ﬁbrillation, prior VTE,
linical evidence of disease or current cardiovascular treat-
ent, and who had an electrocardiogram documenting sinus
hythm. These subjects were assessed by careful examina-
ion of their medical histories and by blood tests.
irculating procoagulant microparticles
lood was collected in the acute phase when the diagnosis
f VTE was assessed and just before anticoagulation was
tarted. Measurement of CPMPs was performed as described
reviously [26], with minor modiﬁcations.
reparation of circulating procoagulant
icroparticle samples
ll microparticle determinations were performed strictly
ccording to Biro et al. [18]. Brieﬂy, citrated blood was
aken soon after admission and centrifuged at 1500 g for
5min at room temperature within the hour after sam-
ling. The supernatant was centrifuged again at 13,000 g
or 2min to avoid platelet contamination. Thrombin and fac-
or Xa inhibitors (d-phenylalanyl-prolyl-arginyl chloromethyl
etone and 1,5-dansyl-glutamyl-glycyl-arginyl chloromethyl
etone, respectively) were added to plasma samples at
ﬁnal concentration of 50M each, and CaCl2 at a ﬁnal
oncentration of 50mM.
uantitation of circulating procoagulant
icroparticles
fter capture of microparticles onto annexin V-coated wells
for 30min at 37 ◦C), taking advantage of the strong afﬁnity
f annexin V for aminophospholipids present in microparti-
les at the calcium concentration used, four washing steps
ere performed with Tris buffer containing 1mM CaCl2 and
.05% Tween 20, each for 5min at 20 ◦C, and the last one
ithout Tween. The phosphatidylserine content of micropar-
icles, directly responsible for their procoagulant activity,
as then measured in a prothrombinase assay. Micropar-
icles were incubated with factor Xa (50 pmol/L), factor
a (360 pmol/L), prothrombin (1.3mol/L) and 2.3mmol/L
aCl2 for 15min at 37 ◦C, and linear absorbance changes
ere recorded at 405 nm after the addition of chromozym
H (380mol/L).
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Quantitation of platelet-derived microparticles and
endothelial-derived microparticles
After speciﬁc capture of PMPs onto anti-glycoprotein Ib
antibody-coated wells and of EMPs onto anti-CD31 antibody-
coated wells, quantitation was achieved after several
washing steps using a prothrombinase assay as described
above. Microparticle levels are expressed as nmol/L of phos-
phatidylserine equivalent.
Miscellaneous measurements
Quantiﬁcation of C-reactive protein was determined by
immunonephelometric tests and circulating brain natri-
uretic peptide levels by enzyme immunoassays.
Transthoracic echocardiography
To evaluate right ventricular dysfunction and haemodynamic
status, transthoracic echocardiography was performed at
the time of admission in all patients with APE. Systolic
transtricuspid pressure gradient and left ventricular ejec-
tion fraction were also measured.
Statistical analysis
Based on previous studies [11,27,28], we hypothesized that
patients with APE would have microparticle levels increased
by approximately two standard deviations compared with
healthy controls and by one standard deviation compared
with subjects without APE but with cardiovascular risk fac-
tors. To achieve this with 90% power and p < 0.05 between
the three groups, 35 subjects per group were required. To
minimize the risk of a type II error and to account for pos-
sible confounders, we recruited in excess of this number of
patients with APE and controls.
Categorical variables, expressed as percentages, were
compared using the Chi2 test or Fisher’s exact test. After a
test for normality, continuous data are expressed as means
and standard deviations or medians with IQRs as appro-
priate. Differences between patients and controls were
evaluated using the two-sample t test or the Mann-Whitney
U test. Correlations between annexin V-positive microparti-
cles and endothelial and platelet microparticle levels were
evaluated using Spearman’s rank correlation coefﬁcients.
The relationship between CPMP levels and patients’
characteristics was estimated using linear regression anal-
ysis (after logarithmic transformation of the dependent
variables) and presented using the estimated regression
coefﬁcient, expressed as percentage increase in micropar-
ticle level for the presence of each risk factor or for a unit
increase in continuous variables, such as age. All analyses
were performed using STATA 9 statistical software (STATA,
College Station, TX, USA). A probability value of 0.05 was
considered statistically signiﬁcant.
ResultsThe baseline characteristics of the three groups are given in
Table 1. The mean age of patients with APE was 67.9± 11.6
years and 66.7% were men. Deep-vein thrombosis was
documented in 71.1% of patients, 26.7% (n = 12) had haemo-
p
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Cigure 1. Levels of circulating procoagulant microparticles in
ontrols with (ControlsCVRFs) and without (ControlsnoCVRFs) cardio-
ascular risk factors and in patients with acute pulmonary embolism
APE).
ynamic instability and 4.4% (n = 2) presented in cardiogenic
hock. APE was submassive in 17 (37.8%) patients. Sixteen
35.5%) patients with APE had at least one transient VTE risk
actor and eight (17.8%) had a permanent risk factor (cancer,
= 3; thrombophilia, n = 5). APE was idiopathic in 21 (46.7%)
atients.
There were no signiﬁcant differences in terms of clini-
al cardiovascular risk factors between patients with APE
nd ControlsCVRFs, except for current smoking (Table 1). In
ontrast, by design, ControlsnoCVRFs were signiﬁcantly dif-
erent from the other two groups with regard to clinical
ardiovascular risk factors. However, there was no signiﬁ-
ant difference regarding age and sex between ControlsCVRFs
nd ControlsnoCVRF, even if there was a slight predominance
f men in the former.
nnexin-positive microparticles in acute
ulmonary embolism patients and controls
nnexin V-positive microparticle levels were higher
n patients with APE (median 4.7 nmol/L, IQR
.9—11.1 nmol/L) than in ControlsnoCVRFs (median
.2 nmol/L, IQR 2.3—4.6 nmol/L; p = 0.02), but there was no
igniﬁcant difference compared with ControlsCVRFs(median
.9 nmol/L, IQR 3.7—8.4 nmol/L; p = 0.99) (Fig. 1). Annexin
-positive microparticle levels were signiﬁcantly higher in
ontrolsCVRFs than in ControlsnoCVRFs (p = 0.01; Fig. 1).
Moreover, after adjustment for age, sex and hyperten-
ion, CPMPs were signiﬁcantly correlated with C-reactive
rotein (p = 0.02) and brain natriuretic peptide levels
p < 0.01), but not with the echographic haemodynamic sta-
us evaluated by systolic transtricuspid pressure gradient
nd left ventricular ejection fraction (Table 2).
latelet-derived microparticles in acute
ulmonary embolism patients and controls
MP levels were not signiﬁcantly different between patients
ith APE (median 2.2 nmol/L, IQR 1.7—5.8 nmol/L) and
ontrolsCVRFs (median 5.5 nmol/L, IQR 2.6—11.3 nmol/L;
398
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Table 1 Baseline characteristics in patients with acute pulmonary embolism and controls with and without cardiovascular risk factors.
Patient characteristics APE (n = 45) ControlsCVRFs
(n = 45)
ControlsnoCVRFs
(n = 45)
P value
APE vs
ControlsCVRFs
APE vs
ControlsnoCVRFs
ControlsCVRFs vs
ControlsnoCVRFs
Age (years) 67.9± 11.6 67.1± 9.9 67.0± 9.5 — — —
Men 30 (66.7) 30 (66.7) 26 (57.8) — 0.38 0.38
Hypertension 25 (55.6) 25 (55.6) 0 — — —
Diabetes mellitus 7 (15.6) 9 (20.0) 0 0.58
< 0.01 < 0.01
Hypercholesterolaemia 19 (42.2) 14 (31.1) 0 0.27 — —
Current smoker 4 (9.1) 16 (35.6) 0
< 0.01
0.04 —
Coronary artery disease 3 (6.8) 9 (20.0) 0 0.07 0.08
< 0.01
History of heart failure 1 (2.2) 0 0 — — —
History of TIA or ischaemic stroke 2 (4.4) 1 (2.2) 0 — — —
History of atrial ﬁbrillation 6 (13.3) 0 0 — — —
Concomitant treatment
Aspirin 8 (17.8) 1 (2.2) — 0.01 — —
Beta-blocker 9 (20.5) 10 (22.2) — 0.84 — —
Calcium channel blocker 6 (13.3) 4 (8.9) — 0.50 — —
Angiotensin-converting enzyme inhibitor 7 (15.9) 7 (15.6) — 0.96 — —
Diuretic 8 (17.8) 0 —
< 0.01
— —
Nitrate 1 (2.2) 1 (2.2) — — — —
Insulin 0 2 (4.4) — — —
Oral antidiabetic therapy 2 (4.4) 6 (13.3) — 0.14 — —
Data are mean± standard deviation or number (%).
APE: acute pulmonary embolism; ControlsCVRFs: controls with cardiovascular risk factors; ControlsnoCVRFs: controls without cardiovascular risk factors; TIA: transient ischaemic attack.
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Table 2 Baseline correlates of annexin V-positive microparticles and platelet and endothelial microparticle levels in 45
patients with an acute pulmonary embolism.
No. of patients (%) Pearson correlation
(95% CI)
% change in MPs
(95% CI)
P value
Annexin V-positive MPs
Clinical presentation
Acute DVT 32 (71.1) 0.07 (−0.02, 0.36) 1.18 (0.59, 2.36) 0.64
Baseline characteristics
Agea 67.9 (11.6) −0.16 (−0.43, 0.14) 0.99 (0.96, 1.01) 0.30
Hypertension 25 (55.6) 0.02 (−0.27, 0.31) 1.05 (0.56, 1.97) 0.89
Diabetes mellitus 7 (15.6) −0.14 (−0.42, 0.16) 0.66 (0.28, 1.56) 0.35
Hypercholesterolaemia 19 (42.2) 0.05 (−0.24, 0.34) 1.12 (0.59, 2.12) 0.73
Current smoker 4 (9.1) 0.26 (−0.04, 0.52) 2.57 (0.89, 7.42) 0.09
Coronary artery disease 3 (6.8) 0.02 (0.28, 0.32) 1.10 (0.31, 3.93) —
Previous atrial ﬁbrillation 6 (13.3) 0.23 (−0.07, 0.49) 2.02 (0.82, 4.06) 0.13
Previous DVT 10 (22.2) 0.16 (−0.15, 0.43) 1.48 (0.70, 3.13) 0.31
Aspirin 8 (17.8) 0.02 (−0.27, 0.31) 1.06 (0.47, 2.4) 0.89
Biological criteria
C-reactive proteina 59.2 (83.7) −0.36 (−0.59, −0.07) 0.995 (0.99, 0.999) 0.02
BNPa,b 279.6 (413.1) 0.45 (0.13, 0.69) 1.001 (1, 1.00) < 0.01
Echographic criteria
LVEF < 40% 3 (6.7) 0.17 (−0.13, 0.44) 2.02 (0.58, 7.01) —
STPGa 135 (307.8) 0.08 (−0.23, 0.37) 1.14 (0.69, 1.89) 0.62
Platelet-derived MPs (anti-GP1b)
Clinical presentation
Shock — 0.37 (0.09, 0.60) 8.17 (1.70, 39.36) —
Acute DVT — 0.16 (−0.14, 0.43) 1.52 (0.71, 3.24) 0.29
Baseline characteristics
Agea — −0.08 (−0.36, 0.22) 0.99 (0.96, 1.02) 0.61
Hypertension — 0.15 (−0.15, 0.42) 1.42 (0.71, 2.84) 0.33
Diabetes mellitus — −0.19 (−0.46, 0.11) 0.54 (0.21, 1.39) 0.21
Hypercholesterolaemia — 0.22 (−0.08, 0.48) 1.67 (0.84, 3.33) 0.15
Current smoker — 0.23 (−0.07, 0.49) 2.55 (0.77, 8.43) 0.13
Coronary artery disease — 0.10 (−0.20, 0.39) 1.59 (0.39, 6.44) —
Previous atrial ﬁbrillation — 0.28 (−0.02, 0.53) 2.57 (0.96, 6.89) 0.07
Previous DVT — 0.17 (−0.13, 0.44) 1.61 (0.70, 3.68) 0.27
Aspirin — 0.14 (−0.16, 0.42) 1.55 (0.63, 3.82) 0.35
Biological criteria
C-reactive proteina — −0.16 (−0.43, 0.14) 1.0 (0.99, 1.00) 0.30
BNPa,b — 0.46 (0.15, 0.69) 1.00 (1, 1.00) < 0.01
Ln MPs 1.62 (1.06) 0.88 (0.78, 0.93) —
Echographic criteria
LVEF < 40% — 0.09 (−0.21, 0.38) 1.54 (0.38, 6.19) —
STPGa — 0.21 (−0.09, 0.48) 1.47 (0.85, 2.54) 0.17
Endothelial-derived MPs (anti-CD31)
Clinical presentation
Shock — 0.28 (−0.02 , 0.53) 8.37 (0.91, 77.2) —
Acute DVT — −0.03 (−0.32, 0.27) 0.91 (0.32, 2.61) 0.87
Baseline characteristics
Agea — 0.02 (−0.27, 0.32) 1.00 (0.96, 1.05) 0.88
Hypertension — 0.08 (−0.22, 0.36) 1.27 (0.49, 3.31) 0.62
Diabetes mellitus — −0.06 (−0.35, 0.24) 0.77 (0.21, 2.86) 0.70
Hypercholesterolaemia — 0.08 (−0.22, 0.37) 1.30 (0.50, 3.49) 0.60
Current smoker — 0.22 (−0.08, 0.49) 3.30 (0.66, 16.42) 0.15
Coronary artery disease — −0.04 (−0.33, 0.26) 0.79 (0.12, 5.31) —
Previous atrial ﬁbrillation — 0.19 (−0.11, 0.46) 2.44 (0.62, 9.65) 0.21
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Table 2 (Suite )
No. of patients (%) Pearson correlation
(95% CI)
% change in MPs
(95% CI)
P value
Previous DVT — 0.13 (−0.17, 0.41) 1.62 (0.52, 5.05) 0.41
Aspirin — 0.02 (−0.28, 0.31) 1.08 (0.31, 3.75) 0.90
Biological criteria
C-reactive proteina — −0.12 (−0.40, 0.18) 0.998 (0.99, 1.00) 0.44
BNPa,b — 0.38 (0.05, 0.64) 1.00 (1, 1.00) 0.03
Ln MPs 1.62 (1.06) 0.53 (0.28, 0.72)
Echographic criteria
LVEF < 40% — 0.09 (−0.21, 0.37) 1.76 (0.26, 11.78) —
STPGa — 0.24 (−0.07, 0.50) 1.84 (0.86, 3.91) 0.12
a Mean.
b n = 34.
BNP: brain natriuretic peptide; CI: conﬁdence interval; DVT: deep-vein thrombosis; GP: glycoprotein; Ln: natural logarithm; LVEF: left
ventricular ejection fraction; MP: microparticle; STPG: systolic transtricuspid pressure gradient.
p = 0.08) (Fig. 2). PMP levels were signiﬁcantly higher in
patients with APE compared with ControlsnoCVRFs (median
1.9 nmol/L, IQR 1.4—2.4 nmol/L of phosphatidylserine
equivalent; p = 0.02) and in ControlsCVRFs compared with
ControlsnoCVRFs (p < 0.001).
After adjustment for age, sex and hypertension, PMPs
were associated with brain natriuretic peptide (p = 0.006)
but not with C-reactive protein levels (p = 0.302). Neither
pulmonary arterial pressure nor left ventricular systolic dys-
function were correlated with PMPs levels (Table 2).
Endothelial-derived microparticles in acute
pulmonary embolism patients and controls
EMP levels were not signiﬁcantly different between patients
with APE (median 0.1 nmol/L, IQR 0.03—0.2 nmol/L) and
Figure 2. Levels of platelet-derived microparticles (PMP) in
controls with (ControlsCVRFs) and without (ControlsnoCVRFs) cardio-
vascular risk factors and in patients with acute pulmonary embolism
(APE).
Figure 3. Levels of endothelial-derived microparticles (EMP) in
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ontrolsCVRFs (median 0.2 nmol/L, IQR 0.1—0.2 nmol/L;
= 0.44) (Fig. 3). EMP levels were not higher in patients with
PE compared with ControlsnoCVRFs (median 0.1 nmol/L, IQR
.01—0.1 nmol/L; p = 0.54). EMP levels in ControlsCVRFs were
ot signiﬁcantly higher than in ControlsnoCVRFs (p = 0.06).
After adjustment for age, sex and hypertension, EMPs
ere only correlated with brain natriuretic peptide levels
p = 0.026) (Table 2).
aseline characteristics and circulating
rocoagulant microparticles
elations between other baseline characteristics and CPMPs
annexin V-positive, PMPs and EMPs) were investigated
mong patients with APE after adjustment for age, sex and
ypertension (Table 2). Current smoking, signiﬁcantly rep-
esented in ControlsCVRFs, (Table 1; p = 0.003), appeared to
nﬂuence CPMP and PMP levels among patients with APE
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(change in microparticles 2.57%, p = 0.09 and 2.55%, p = 0.13,
respectively).
Discussion
To our knowledge, this is the ﬁrst study to compare CPMP
levels and their phenotypes (using a functional assay based
on prothrombinase) in APE patients. Comparing APE patients
with two different control groups, our study design allowed
us to analyse the relative effect of cardiovascular risk fac-
tors and APE on microparticle levels. In APE patients, CPMP
procoagulant activity is signiﬁcantly increased compared
with the physiological status represented by a population
with no prior thrombotic events or cardiovascular risk fac-
tors (p = 0.02). Nevertheless, procoagulant activity related
to CPMPs in APE patients was not signiﬁcantly different to
that in ControlsCVRFs.
Microparticles and venous thromboembolism
VTE results from an imbalance between procoagulant,
anticoagulant and ﬁbrinolytic activities. Platelet and
endothelial microparticles are considered markers of ongo-
ing or recent endothelial cell and platelet activation,
or apoptosis. Microparticle procoagulant activity, mainly
related to tissue factor activity in the presence of phos-
phatidylserine phospholipids, is dependent on the cellular
origin, the initial stimulus and the secondary microparticle-
induced cell activation [4,18,29]. Experimental animal
studies with high-resolution online videomicroscopy have
revealed that circulating microparticles mediate the accu-
mulation of tissue factor on platelet-rich thrombi, and also
in the venous thrombosis model [18,30]. Demonstrating the
increased procoagulant activity related to CPMPs in APE
patients vs ControlsnoCVRF, our results argue in favour of their
functional participation in venous thrombogenesis in the
interface of soluble coagulants factors, circulating cells and
dysfunctional endothelium. As far as microparticle subtypes
are concerned, only PMPs appeared to be signiﬁcantly ele-
vated in APE patients vs ControlsnoCVRF. We have to take into
account the lower detection limits in the estimation of EMP
involvement in APE to interpret this result, in terms of the
variability in antibody afﬁnity (CD31 vs CD62E or CD144), as
in the availability of the antigen or in the level of endothelial
markers borne by microparticles [31]. However, this feature
has been used in studies reported by other groups to mea-
sure EMPs (CD31) and PMPs (glycoprotein 1b) distinctly [16].
In the future, more speciﬁc endothelial phenotypes, such as
CD62E/CD144/CD146, should be targeted as a priority.
Data emerging from the literature are quite discordant
concerning microparticles and phenotypes involved in APE,
mainly because of the different techniques and method-
ological approaches used. To our knowledge, there are two
previous clinical reports on this subject that differ from our
study in terms of the design, the method of microparticle
quantitation, the population studied and the comparator
used [16,17]. In addition, increasing data correlated the
risk of deep-vein thrombosis in patients with cancer to
tissue factor-bearing tumour cell-derived microparticle lev-
els measured by functional test or ﬂow cytometry, with a
pathophysiological role supported by P-selectin glycoprotein
t
u
t
a
o401
igand 1 (or other mucinous glycoproteins) and P-selectin
nteraction [21,23].
elation between cardiovascular risk factors
nd microparticles in venous
hromboembolism
ur observations highlight the importance of adjusting for
he presence of cardiovascular risk factors in conditions in
hich microparticle levels are raised.
Diabetes [13,15,32] and hypertension [14] are associated
ith endothelial dysfunction and platelet activation, and
ncrease CPMP levels. In a previous report, our group [15]
ound a higher level of CPMPs in patients with type 2 dia-
etes compared with healthy subjects. A strong positive
orrelation was also found between endothelial and platelet
icroparticle levels on the one hand, and the absolute
evel of both systolic and diastolic blood pressures on the
ther [14]. These ﬁndings and the present data emphasize
hat cardiovascular risk factors, especially hypertension,
re confounders in the previously described relationship
etween circulating microparticles and VTE disease [16,17].
We suggest several hypotheses to account for the intrigu-
ng lack of difference in CPMP procoagulant activity between
ases and ControlsCVRFs. First, we could consider the pre-
ominant role of cardiovascular risk factors as vascular cell
ctivators vs venous thrombosis risk factors such as hypox-
emia induced by blood stasis. A second hypothesis relies on
n expected difference in microparticle consumption kinet-
cs between both populations, which would be faster in
ases of an acute thrombotic event, such as venous thrombo-
is [22,33—35]. Indeed, the production and consumption of
icroparticles are mainly local processes in the acute phase
f VTE. This is in line with the recent experimental study by
amacciotti et al., demonstrating not only variable kinetics
or each subtype of microparticle, but also their evolutive
hrombogenicity during the thrombotic process itself [19].
he sequestration of microparticles in the forming throm-
us is also a diluting factor [23]. The last hypothesis is an
nderestimation of the CPMP effective procoagulant activ-
ty due to a lack of sensitivity with our test using a speciﬁc
uantiﬁcation of microparticle-linked phosphatidylserine in
functional assay, compared with tissue factor activity eval-
ation [36].
icroparticles: cause or consequence in
enous thrombogenesis?
y evaluating microparticle-related procoagulant activity in
nly the acute phase of venous thrombosis, our study is
nable to assess whether CPMPs have a causal role in venous
hrombogenesis. Nevertheless, we found some interesting
orrelations.
The PMP subtype appeared to be an important source
f procoagulant microparticles, and was correlated with
PMPs. This is in line with the hypothesis of platelet activa-
ion and participation in venous thrombogenesis as has been
nderlined recently in the literature [2,3], linking venous
hrombosis to atherothrombosis. PMPs levels have been
ssociated positively with thrombus weight and proteomics
f microparticles after VTE revealed the upregulation of Gal
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BP, a polypeptide from lectin family that plays a key role in
uman platelet aggregation and function, promoting shed-
ing of microparticles and generation of leucocyte-platelet
ggregates [37].
In parallel, we observed a tendency towards an asso-
iation of CPMPs and PMPs with severe clinical status, in
ccordance with brain natriuretic peptide levels, but weakly
inked with C-reactive protein, an inﬂammatory marker with
poor negative predictive value in pulmonary embolism
38,39]. Recently, two studies correlated the severity of pul-
onary hypertension with CPMP levels in pulmonary artery
lood samples [31,40].
Finally, after adjustment for age, sex and hypertension,
PMPs and PMPs appeared to be correlated in our cases
ith current smoking, a major cardiovascular risk factor in
therothrombosis. Moreover, Pomp et al. [41] showed that
urrent smoking remained a risk factor for venous thrombo-
is among young people after adjustment for age, sex and
ody mass index. In the literature, an increasing amount of
vidence suggests the likelihood of a link between arterial
nd venous disease [42]. According to results from recent
tudies, atherosclerosis and VTE share common risk fac-
ors, including age, obesity and current smoking [43,44].
n a large population-based study, Sorensen et al. [45]
rovided strong evidence that patients with VTE are at
ncreased risk of subsequent arterial cardiovascular events
ompared with population controls, which is most pro-
ounced during the ﬁrst year of follow-up. This is consistent
ith underlying common prothrombotic mechanisms such
s thrombogenesis, endothelial damage and inﬂammation
46].
tudy limitations
e did not evaluate the post-VTE prothrombotic state
elated to CPMPs using a second measure of CPMP procoag-
lant activity during the ﬁrst year of follow-up. Moreover,
aking into account the limitation of our test related to
he choice of CD31 as single endothelial phenotypic marker
47,48], we should also consider the involvement of other
icroparticles subtypes, such as leukocyte microparticles.
everal studies demonstrated that platelets, leukocytes and
ndothelial cells colocalize and interact in the milieu of a
orming thrombus [49—52]. By binding the PSGL-1 counter
eceptor via P-selectin, platelets and PMPs could activate
onocytes, enhancing tissue factor expression and proco-
gulant leukocyte microparticle release [53]. As suggested
y experimental studies in vivo, leukocyte microparticle
elease might play a key role in thrombus initiation to
ascular remodelling, and we are going to evaluate their
rocoagulant activity in APE [19,49]. Finally, we might have
nderestimated the procoagulant activity related to CPMP
y using a prothrombinase assay, whereas the estimation of
issue factor procoagulant activity would be more relevant
36].onclusions
ur study conﬁrms the correlation between APE and CPMPs
hrough their own procoagulant functionality, relying mainly
n platelet activation. This relation no longer holds true
[L. Bal et al.
hen patients with APE are compared with those with car-
iovascular risk factors, stressing the fact that potential
onfounders should be taken into account when microparti-
le levels are analysed in VTE.
Further research is needed to demonstrate in which con-
itions (i.e., initial stimuli, cell origin, etc.) the circulating
ool of microparticles could be sufﬁcient to precipitate a
enous thrombotic event and to evaluate the therapeutic
mplications.
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